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ABSTRACT
Neuroinflammation is one of the main physiopathological
mechanisms of amyotrophic lateral sclerosis (ALS), produced by
the chronic activation of microglia in the CNS. This process is
triggered by the persistent activation of the ATP-gated P2X7 receptor
(P2RX7, hereafter referred to as P2X7R). The present study aimed to
evaluate the effects of the chronic treatment with the P2X7R
antagonist JNJ-47965567 in the development and progression of
ALS in the SOD1G93A murine model. SOD1G93A mice were
intraperitoneally (i.p.) injected with either 30 mg/kg of JNJ-
47965567 or vehicle 4 times per week, from pre-onset age (here,
postnatal day 60; P60) until study endpoint. Body weight, motor
coordination, phenotypic score, disease onset and survival were
measured throughout the study, and compared between vehicle- and
drug-injected groups. Treatment with the P2X7R antagonist JNJ-
47965567 delayed disease onset, reduced body weight loss and
improved motor coordination and phenotypic score in female
SOD1G93A mice, although it did not increase lifespan. Interestingly,
neither beneficial nor detrimental effects were observed inmales in any
of the analyzed parameters. Treatment did not affect motor neuron
survival or ChAT, Iba-1 and P2X7R protein expression in endpoint
individuals of mixed sexes. Overall, chronic administration of JNJ-
47965567 for 4 times per week to SOD1G93A mice from pre-onset
stage altered disease progression in female individuals while it did not
have any effect in males. Our results suggest a partial, yet important,
effect of P2X7R in the development and progression of ALS.
KEY WORDS: Amyotrophic lateral sclerosis, SOD1G93A mice,
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an adult-onset and
heterogeneous neurodegenerative disorder characterized by gradual
loss of muscle function, spasticity and weakness, cramps and muscle
wasting, speech and swallowing impairment, compromised
respiration, progressive paralysis and death within 3-5 years after
diagnosis (Calvo et al., 2014; Hardiman et al., 2017). So far, riluzole
and edaravone are the only two approved drugs that show verymodest
clinical benefits in patients (Doble, 1996; Cruz, 2018). Therefore, this
fatal disease still remains incurable, and there is urgent need to
discover new drugs that can improve the quality of life and life
expectancy of patients suffering from this devastating disease.
Multiple signaling pathways converge to cause the progressive
degeneration of upper motor neurons (neurons projecting from the
motor cortex to the brainstem and spinal cord) and lower motor
neurons (neurons projecting from the brainstem or spinal cord to
muscle), the cause for the phenotypic symptoms in ALS patients
(Bonafede and Mariotti, 2017; Hardiman et al., 2017). One of the
involved pathways is chronic neuroinflammation, which has been
found in patients with ALS, post-mortem samples and rodent
models of ALS (Corcia et al., 2012; Brites and Vaz, 2014).
The purinergic P2X7 receptor (P2RX7, hereafter referred to as
P2X7R) plays a key role in the neuroinflammatory process. The
activation of the receptor through high concentrations of ATP
released by damaged neurons results in the assembly of the NLRP3
inflammasome complex in microglia and the subsequent release of
pro-inflammatory cytokines, such as IL-1β (DiSabato et al., 2016;
Swanson et al., 2019). The upregulation of P2X7R in ALS patients
suggests its implication in disease progression (Yiangou et al.,
2006). Moreover, stimulation of P2X7R with ATP or 3′-O-(4-
Benzoyl)benzoyl ATP (BzATP) triggers a neurotoxic phenotype in
astrocytes, inducing motor neuron death which is prevented by the
P2X7R antagonist Brilliant Blue G (BBG) (Gandelman et al.,
2010). These in vitro experiments also point out to a role of the
P2X7R receptor in ALS disease. Furthermore, ATP stimulation of
the microglial P2X7R from SOD1G93A mice promotes the
stimulation of NADPH oxidase 2 (NOX2) and kinases ERK1/2,
with a concomitant increase of ROS (Apolloni et al., 2013b).
However, short stimulation of P2X7R causes the activation of
autophagy and upregulation of anti-inflammatory markers in
microglia of SOD1G93A mice (M2 microglia), whereas persistent
stimulation impairs the autophagic flux that might correspond to the
change to a pro-inflammatory phenotype (M1 microglia),
suggesting a dual functional role of the receptor in the pathway
(Fabbrizio et al., 2017). Thus, P2X7R seems to play a major role in
ALS pathogenesis. In this context, receptor blockade with
antagonists has been proposed as a new therapeutic approach to
treat the disease.
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This hypothesis has already been tested in vivo in the SOD1G93A
mouse model of ALS (summarized in Table 1), the most used model
in preclinical stages owing to its high resemblance to the human
pathology (Gurney et al., 1994; Philips and Rothstein, 2015; Lutz,
2018). In a first study, Cervetto and colleagues (Cervetto et al.,
2013) showed that treatment with BBG (i.p., 45.5 mg/kg, every
2 days) starting at postnatal day 90 (P90) improved motor
coordination in males and females and reduced body weight loss
in males. In a second study, BBG was administered at the higher
dose of 250 mg/kg, 3 times per week. When treatment was initiated
at P100, delayed disease onset, improved motor performance,
reduced microgliosis and enhanced motor neuron survival were
observed. However, this was not the case when treatment was
initiated at earlier stages (Apolloni et al., 2014). A lower BBG dose
(45.5 mg/kg, 3 times per week) was used in a third study, starting at
disease pre-onset time, i.e. P62-P64. Reduction in body weight loss
and survival was observed in females but not in males, while motor
performance was unaffected in either sex (Bartlett et al., 2017).
Altogether, these studies suggest that P2X7R plays an important
role in ALS progression. However, due to the low selectivity of
BBG (Bo et al., 2003; Seyffert et al., 2004; Qiu and Dahl, 2009; Jo
and Bean, 2011), the efficacy of other antagonists was then
evaluated. Application of the more-potent and selective P2X7R
blocker A-804598 from P100 onwards (30 mg/kg, 5 times per
week), did not produce any differences in motor performance,
disease onset or survival (Fabbrizio et al., 2017). Similar results
were obtained after administration of the P2X7R antagonist JNJ-
47965567 (Fig. 1; 30 mg/kg, 3 times per week) from P100 onwards
(Ly et al., 2020).
Despite the negative results obtained by Ly and collaborators
(Ly et al., 2020), we decided to further evaluate the effects of this
brain-penetrant antagonist in SOD1G93A mice because JNJ-
47965567 had shown promising effects in models of mania and
neuropathic pain, as well as high potency, selectivity and capacity to
block IL-1β release (Bhattacharya et al., 2013). The aim of this
present study was to evaluate the effects of chronic administration of
30 mg/kg of JNJ-47965567, 4 times per week from postnatal day 60
(P60) or pre-onset. This treatment was able to delay disease onset,
reduce body weight loss, improve motor coordination and
neurological scores in female SOD1G93A mice, although no effects
were observed in male mice.
RESULTS
Treatment with JNJ-47965567 delays disease onset in
female SOD1G93A mice
To assess whether JNJ-47965567 treatment can delay disease onset
in SOD1G93A mice, 24 males and 26 females were i.p. injected
from pre-symptomatic stage (P60) until the humane endpoint was
reached. Of these, 11 males and 12 females were treated with
vehicle (30% SBE-β-cyclodextrin), and 13 males and 14 females
Table 1. Summary of the phenotypic clinical outcomes emanating from 5 previous studies and the present one, upon chronic administration of
P2X7R blockers BBG, A-804598, or JNJ-47965567 to SOD1G93A
Reference Treatment Treatment starting point Main outcomes
Cervetto et al.,
2013
BBG, 45.5 mg/kg, every
48 h, i.p.
P90 (pre-onset) to humane endpoint • Improvement in motor performance in both sexes, although
greater effect in males.
• Delayed weight loss in males.





P100 (late pre-onset) and P135 (onset) to
humane endpoint
• Improvement in motor performance in mice treated from onset (no
differences between sexes).




P40 (asymptomatic), P70 (pre-onset),
P100 (late pre-onset) to humane
endpoint
• Delayed disease onset, improved ALS score and motor
performance in mice treated from late pre-onset (no differences
between sexes).
• No differences in survival (no differences between sexes).
• Decrease in microgliosis, inflammatory markers andmotor neuron






P60 (pre-onset) to humane endpoint • Reduced body weight loss and prolonged survival in females.






P100 (pre-onset) to humane endpoint • No effect on motor performance, ALS score or survival observed
(only female mice included in the study).
Ly et al., 2020 JNJ-47965567, 30 mg/
kg, 3 times/week, i.p.
P100 (onset) to humane endpoint • No effect on motor performance, ALS score or survival observed
(no differences between sexes).
• No altered gene expression in spinal cord (no differences between
sexes).
• No altered proportions of lymphoid leukocytes (differences
between sexes not assessed).
• No effect on serum cytokines (differences between sexes not
assessed).
Present study JNJ-47965567, 30 mg/
kg, 4 times/week, i.p.
P60 (pre-onset) to humane endpoint • Delayed disease onset, reduced body weight loss, improved
motor coordination and ALS score in females.
• No effect on survival (no differences between sexes).
• No effect onmotor neuron survival (differences between sexes not
assessed).
• No altered protein expression (differences between sexes not
assessed).
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with 30 mg/kg of JNJ-47965567, administered i.p. 4 times per week
(Fig. 2). Disease onset was defined as the day of consecutive weight
loss after three weight measurements without recovery, a direct sign
of muscle mass loss, degeneration and disease progression (Ludolph
et al., 2010). Kaplan–Meier plots of disease onset indicates clear
differences upon statistical comparisons (Fig. 3). Treatment with
JNJ-47965567 delayed disease onset in SOD1G93A mice when both
sexes were analyzed together (Fig. 3A; 123.7±3.0 days for vehicle
and 134.0±2.7 for treated mice, P=0.007). However, when such
analysis was performed separately, treatment did not modify disease
onset in the male subset of the animals (Fig. 3B; 120.5±4.2 for
vehicle and 122.2±2.9 for treated mice, P=0.653). Strikingly,
treatment significantly delayed disease onset in females, i.e. the
difference observed was greater than when both sexes
were analyzed as a whole (Fig. 3C; 126.7±4.3 days for vehicle
and 144.9±1.7 for treated mice, P<0.001).
Treatment with JNJ-47965567 reduced body weight loss in
female SOD1G93A mice
To study body weight loss – a marker of disease progression in ALS
and of muscle loss (Ludolph et al., 2010; Cervetto et al., 2013) –
mice included in the study were weighed 4 times per week, as
detailed in the Materials and Methods.
As shown in Fig. 4A, JNJ-47965567 was able to reduce body
weight loss in the whole set of animals (P=0.02). However, no
difference regarding body weight was observed when treated males
were analyzed independently (Fig. 4B; P=0.97). In line with the
results presented for the disease onset, treatment with JNJ-
47965567 significantly reduced body weight loss in females
(Fig. 4C; P<0.001).
Treatment with JNJ-47965567 improvedmotor performance
in female SOD1G93A mice
Having observed a delayed disease onset and a milder weight loss, it
was expected that JNJ-47965567-treated mice would exhibit a better
motor performance in comparison with vehicle-treated mice. As
previously detailed, motor performancewas evaluated twice per week
with the RotaRod apparatus, which measures motor coordination, and
4 times per week with the neurological test NeuroScore.
Results obtained by using the RotaRod are shown in Fig. 5,
expressed as the latency to fall (in seconds) and normalized as the
percentage of the values obtained the first day of treatment. Similar
to results regarding disease onset and body weight, the RotaRod test
revealed differences between vehicle and JNJ-47965567-treated
mice. The combined analysis of males and females revealed a higher
latency time in treated mice (Fig. 5A; P=0.04). Such difference was
lost when separately analyzing male data (Fig. 5B; P=0.50), and
reappeared more clearly when female data were analyzed separately
(Fig. 5C; P=0.02).
Similar results were observed for the phenotypic test NeuroScore,
which measures disease progression (Fig. 6). In this case, no
differences were observed when males and females were analyzed
together (Fig. 6A; P=0.14), nor when males were independently
considered (Fig. 6B; P=0.25). However – and following the trend
observed in disease onset, weight loss and motor coordination –
treatment significantly delayed disease progression in the female
subset of animals, as shown in Fig. 6C (P<0.001).
Treatment with JNJ-47965567 did not affect the survival of
SOD1G93A mice
To conclude the analysis of the clinical effects of the treatment, we
wondered whether the chronic administration of JNJ-47965567 can
extend the lifespan of the animals. For this matter, survival was
defined by the number of days elapsed until animals reached the
humane endpoint of the study or a NeuroScore (NS) 4 (see Materials
and Methods).
Kaplan–Meier survival curves are plotted in Fig. 7. The
combined analysis of males and females showed no difference in
survival between vehicle- and JNJ-47965567-treated mice (Fig. 7A;
168.9±3.1 for vehicle- and 169.8±2.2 for JNJ-47965567-treated
mice, P=0.779). In the case of males, vehicle-treated mice showed a
tendency to live longer than those administered with JNJ-47965567,
although this difference was not statistically significant (Fig. 7B;
169.9±4.9 for vehicle- and 165.3±3.2 for JNJ-47965567-treated
mice, P=0.178). The opposite occurred with females treated with
Fig. 1. Molecular structure of compound JNJ-47965567. The compound
was administered at a concentration of 30 mg/kg in 30% SBE-β-cyclodextrin.
Fig. 2. Protocol followed for the blinded
chronic i.p. administration of vehicle (30%
SBE-β-cyclodextrin) and JNJ-47965567.
Animals were trained for 3 consecutive days in
the RotaRod apparatus just before the
commencement of the treatment. At P60, mice
were divided into two treatment groups
(Vehicle or JNJ-47965567) and
administrations continued 4 times per week
until the humane endpoint. Disease
progression was followed according to the
protocol by assessing motor coordination with
RotaRod, by measuring body weight and
according to the phenotypic NeuroScore test
(see Materials and Methods). At the humane
endpoint, mice were euthanized, and spinal
cords were dissected and stored until used. All
tests were blinded for the investigators
involved.
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JNJ-47965567; these tended to live longer than vehicle-treated
mice, although no statistical difference was observed (Fig. 7C;
167.9±4.1 for vehicle- and 174.0±2.8 for JNJ-47965567-treated
mice, P=0.274).
Treatment with JNJ-47965567 did not improvemotor neuron
viability of endpoint SOD1G93A mice
Next, we wondered whether JNJ-47965567 treatment was able to
increase motor neuron survival in the spinal cord of SOD1G93A mice.
Cell bodies of neurons that stained positively for choline
acetyltransferase (ChAT) were considered to be and counted as motor
neurons. Treatment with JNJ-47965567 was unable to reduce motor
neuron loss in the analyzed mixed sex group of animals of P=0.816,
n=6 at the humane endpoint of the study (Fig. 8C). However, the
reduction in the number of motor neurons was evident and significant
when comparing WT individuals and SOD1G93A mice (P<0.001).
Clear morphological abnormalities were found in endpoint SOD1G93A
mice (Fig. 8D-G), which were not present in age-matchedWT animals
(Fig. 8A,B). A lower number of motor neurons, some of which showed
clear signs of degeneration, was present in ALS animals (Fig. 8A,D,G);
also observed were vacuolation and/or beading and swelling of
neuronal processes (Fig. 8B,E).
Treatment with JNJ-47965567 did not modify protein
expression of endpoint SOD1G93A mice
To assess whether treatment was diminishing microglial activation
and proliferation, we studied the expression of the microglial marker
allograft inflammatory factor 1 (AIF1, hereafter referred to as Iba-1).
Likewise, we then determined whether the administration increased
motor neuron survival by analyzing expression of the motor neuron
marker ChAT. Last, we checked whether P2X7R expression or the
levels of mutated human SOD1 were affected by the treatment.
These four parameters were analyzed in endpoint female SOD1G93A
mice by western blotting. No differences were observed between
vehicle- and JNJ-47965567-treated females regarding the
expression of any of the analyzed proteins (n=3, Fig. S1).
DISCUSSION AND CONCLUSIONS
In this study, we analyzed the effects that chronic administration of
the selective, potent and brain-penetrant P2X7R antagonist JNJ-
47965567 has on the SOD1G93A mouse model of ALS.
Administration of the antagonist was able to delay disease onset,
reduce body weight loss and improve motor performance in female
individuals, although no effect was observed in males. No
differences were observed regarding motor neuron survival and
protein expression at the humane endpoint in animals of a mixed
sex group.
Our results are generally in line with previously published data,
although it is crucial to highlight the differences found between the
studies, which are summarized in Table 1. First published studies
assessed the effect of chronic administration of the antagonist BBG.
Cervetto and colleagues Cervetto et al., (2013) reported improved
motor performance in both sexes, which in this case, was found
more predominant in males when compound administration started
Fig. 3. Disease onset of SOD1G93A ALSmice administered i.p. 4 times per week with vehicle (orange) or 30 mg/kg JNJ-47965567 (green).Disease onset
was defined as the time mice were losing weight for 3 consecutive days. (A) Kaplan–Meier plot showing disease onset probability in the whole group of mice.
(B) Kaplan–Meier plot showing onset probability in the subset of male mice. (C) Kaplan–Meier plot showing onset probability in the subset of female mice. Data
analysis was performed using Cox regression, introducing age at first injection as co-variables. Differences were considered as statistically significant at P<0.05.
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at P90 or pre-onset. In contrast to our results, reduced weight loss
was also reported in the subgroup of males but not in females. The
administration of BBG also delayed disease onset in mice when
administered from P100 onwards or late pre-onset, but no
differences between sexes were observed (Apolloni et al., 2014).
A reduction in body weight loss, accompanied by prolonged
survival was found in females when BBG treatment started at P60 or
pre-onset, although disease onset and motor performance were not
modified (Bartlett et al., 2017). Even though these results point to a
possible implication of P2X7R in ALS progression, their disparity is
striking. These discrepancies could be due to the differences in
dosing, starting-point of administration and the use of BBG itself.
Although BBG is widely used in vitro and in vivo as a P2X7R
antagonist, it is not selective for this receptor, as it is known to target
P2X1R (Seyffert et al., 2004), P2X5R (Bo et al., 2003), P2X4R,
voltage-gated sodium channels (Jo and Bean, 2011), as well as the
ATP-release channel pannexin-1 (Qiu and Dahl, 2009). Therefore,
there is no clear evidence that the benefits of BBG treatment are only
due to P2X7R inhibition; they might be a consequence of targeting
any of the other routes. However, our results can be directly linked to
the blockade of P2X7R, as JNJ-47965567 is a very potent and CNS-
permeable antagonist, with very high selectivity for P2X7R, as well
as high target engagement and efficacy at the dose used.Moreover, its
way of administration has already been demonstrated (Bhattacharya
et al., 2013).
However, a recently published article that described the chronic
administration of JNJ-47965567 to SOD1G93A mice did not report
any beneficial outcomes (Ly et al., 2020). The differences between
the above mentioned study and our study here is that Ly and
colleagues performed compound administration 3 times per week
from onset or P100, whereas in our current study, mice received
antagonist injections 4 times per week at pre-symptomatic stage or
P60 onwards. The very surprising difference in results between the
two studies reveals the great importance of study design, and
suggests that a constant and consistent blockade of the P2X7R is
crucial for the therapeutic effect to take place in SOD1G93A mice. It
has been shown that JNJ-47965567 has a residence time in the CNS
of ∼2-4 h after a 30 mg/kg i.p. dose (Jimenez-Pacheco et al., 2016).
Thus, administration of the compound 4 times per week might be
better in order to maintain specific drug concentrations in the CNS
and the antagonism of the receptor. Therefore, an even more
frequent dosage, such as every 24 h, or the use of a different
antagonist with longer residence time in the CNS, could be more
suitable for the blockade of P2X7R and treatment of SOD1G93A
mice.
Another experiment showing the importance of study design and
the selection of the antagonist is that of the chronic administration of
A-804598 – a CNS-permeable, potent and selective antagonist – to
SOD1G93A mice from P100 or at pre-onset, 5 times per week. In
contrast to our results, this treatment did not exert any beneficial
effect (Fabbrizio et al., 2017). As the potencies of JNJ-47965567
and A-804598 are similar and since they have the same binding site,
the discrepancy in these results could be due to the reduced brain-to-
plasma ratio of the latter compared with that of JNJ-47965567
Fig. 4. Variation in body weight of SOD1G93A mice during the treatment. Vehicle-treated mice are shown in orange; JNJ-47965567-treated mice are
represented in green. (A) Body weight variation in the whole group of mice. (B) Body weight variation in the subset of male mice. (C) Body weight variation
in the subset of female mice. Data are presented as mean±s.e.m. Data analysis was performed with unpaired t-test or Mann–Whitney test, depending on the
normality of the data, and differences were considered statistically significant at P<0.05.
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(Bhattacharya et al., 2013; Karasawa and Kawate, 2016).
Differences could also be due to the distinct starting point of
administration as, in this case, the administration was performed at
late pre-onset stages of the disease.
Owing to the high heterogeneity of treatment starting-points
between the aforementioned works, drawing conclusions about the
best time to start the treatment is challenging. However, it is evident
that treatment start points substantially influence study outcomes.
These differences could be due to the disparate activation states
developed by microglia in response to P2X7R activation. Microglia
are highly dynamic and plastic cells that are extremely sensitive to
the smallest perturbation and that undergo irreversible imprinting
towards anti-inflammatory (M2) or pro-inflammatory (M1)
phenotypes (Walker and Lue, 2015; Parisi et al., 2016; Tang and
Le, 2016). A recent study has shown that treatment with the P2X7R
agonist BzATP at late pre-onset or P105 helps to preserve
neuromuscular junction morphology, and delays denervation and
atrophy in SOD1G93A mice (Fabbrizio et al., 2020). Moreover,
ablation of P2X7 receptor in SOD1G93A mice exerted a detrimental
effect in disease progression and increased pro-inflammatory
markers (Apolloni et al., 2013a). Therefore, to find biomarkers
that can reflect the activation state of microglia during ALS
progression would help to determine the best time to start treatment.
Also, due to the differences between mice strains of individual
laboratories, i.e. different phenotypic symptoms at variable
postnatal days (see Table 1), it would be very useful for future
works to specifically explain the state of the animals when treatment
commences; that is not only as ‘days after birth’ but also by defining
symptoms. Especially the latter can more easily be related to the
individual state of each animal and could reduce heterogeneity.
Another remarkable outcome of our study is the sex difference in
relation to treatment, which has been pointed out previously
(Cervetto et al., 2013; Bartlett et al., 2017). This sex-specific effect
could be due to the contribution of sex hormones, known to play a
key role in metabolism (Bame et al., 2012). The implication of
hormones could be further assessed by using our experimental set-
up but with ovariectomized or castrated animals. However, these
differences could also be due to the use of the SOD1G93A model
itself, as differences in terms of disease progression, onset and
survival have been reported in this mouse strain, as well as in
patients carrying mutations of SOD1 (Pfohl et al., 2015; Tang et al.,
2019). Therefore, to confirm the validity of the results observed with
our model, the experiment could be repeated by using different
transgenic mouse models, e.g. TDP-43A315T (White et al., 2018) or
h(G4C2)37-500 (Liu et al., 2016), carrying mutations in different
proteins [TAR DNA-binding protein 43 (TARDBP) or guanine
nucleotide exchange C9orf72 (CI072), respectively].
Even though some differences in molecular outcomes after
treatment with BBG have been reported, such as reduced
microgliosis, and decreased inflammatory markers and motor
neuron loss (Apolloni et al., 2014), we did not observe any of
these differences between JNJ-47965567-treated and vehicle-
Fig. 5. Evaluation of motor coordination by using the RotaRod apparatus. Latency to fall on each time-point is presented as the percentage of the
latency of the first day, considered as maximum. Mice administered with vehicle are shown in orange; JNJ-47965567-treated mice are represented in green.
(A) Variation in latency to fall in thewhole group of mice. (B) Variation in latency to fall in the subset of males. (C) Variation in latency to fall in the subset of females.
Data are presented as mean±s.e.m. The analysis was performed with unpaired t-test or Mann–Whitney test, depending on data normality, and differences
were considered statistically significant at P<0.05.
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treated mice. The lack of difference in terms of protein expression is
in line with the differences observed when treating 3 times per week
with JNJ-47965567 (Ly et al., 2020). However, in our case, it could
also be explained by the reduced number of animals analyzed (n=3),
as a higher number of mice are needed to yield stronger conclusions.
As initially expected given the experimental design, we found no
difference between treatments regarding the number of motor
neurons. As all tissue samples were taken at the humane endpoint,
we had expected that all the animals would reach the same level of
degeneration, independently of treatment duration or type of
compound administered. Therefore, it is possible that our treatment
routine yielded a mild beneficial effect regarding clinical outcome,
which is not necessarily reflected in motor neuron survival or protein
expression. In this regard, a protocol according to which all animals
were euthanized at the same pre-defined post-injection day could help
to discern the effect of P2X7R antagonism at the molecular level and
in terms of motor neuron survival.
In conclusion, the current study demonstrates that chronic
administration of the P2X7R antagonist JNJ-47965567, 4 times
per week from pre-onset until the humane endpoint delayed
disease onset, reduced body weight loss and improved motor
parameters in female SOD1G93A mice. However, treatment did not
show any benefit on males and did not affect motor neuron
survival, neither in females nor in males. The outcomes of this
study could be useful for the design of new preclinical studies that
use P2X7R antagonists with better pharmacokinetic profiles, and
to understand the role of this receptor in the pathogenesis and
eventual treatment of ALS.
MATERIALS AND METHODS
Animals
Mouse experiments were performed with the approval of the Ethics
Research Committee of Universidad Autónoma de Madrid (Spain) and
according to the code of ethics and guidelines established by European
Community Directive (2010/63/EU) and Spanish legislation (RD53/2013).
Mice hemizygous for the human SOD1G93A transgene and back-crossed (>5
generations) onto a C57BL/6J background [B6.Cg-Tg (SOD1*G93A)
1Gur/J] were originally provided by Josep E. Esquerda (Universidad de
Lérida, Spain).
Mice were bred and maintained at the Animal Facility of the Medical
School, Universidad Autónoma de Madrid, Madrid (Spain). At weaning,
transgenic SOD1G93A mice were genotyped as previously described
(Apolloni et al., 2013a) and housed in a temperature-controlled
environment on a 12:12 h light-dark cycle. SOD1G93A mice were
matched for age and sex, and randomly divided into two treatment
groups, JNJ-47965567 (Fig. 1) and vehicle. They were caged with paired
littermates, with 4-5 females or 2-3 males per cage (unless fighting
required separation). Food and water were available ad libitum. The
development of symptoms was closely monitored using the neurological
NeuroScore (NS) test that classifies mice from 0 (i.e. pre-symptomatic) to
4 (endpoint state) (Hatzipetros et al., 2015). When mice became
symptomatic and were unable to access water and food (NS 2), longer
sippers were placed onto water bottles and food pellets placed directly onto
the cage floor.
Fig. 6. Disease progression evaluated according to the NeuroScore test, ranging from 0 (i.e. presymptomatic) to 4 (i.e. endpoint). Graphs show
individual scores over the duration of the disease; the mean is represented by a thin line. Mice administered with vehicle are shown in orange; JNJ-47965567-
treated mice are represented in green. (A) NeuroScore variation in the whole group of mice. (B) NeuroScore variation in the subset of male mice.
(C) NeuroScore variation in the subset of female mice. Data analysis was performed with unpaired t-test or Mann–Whitney test, depending on data normality,
and differences were considered statistically significant at P<0.05.
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Administration of JNJ-47965567 and vehicle
JNJ-47965567 was provided by Janssen Pharmaceutica NV (Beerse,
Belgium) and was prepared at a concentration of 5 mg/ml in 30% SBE-β-
cyclodextrin. SBE-β-cyclodextrin was first provided by Janssen
Pharmaceutica NV (Beerse, Belgium) and then purchased from Cydex
Pharmaceuticals. To prepare the solution, the compound was weighed,
dissolved in 2 equivalents of HCl (37%) and further diluted in SBE-β-
cyclodextrin and adjusted to pH 4-4.5. Both solution and vehicle (30%
SBE-β-cyclodextrin) were filter sterilized through 0.22 μm filters
(Merck-Millipore) and used within one week. Mice were injected
intraperitoneally (i.p.) 4 times per week (evenly distributed during the
week), starting at pre-symptomatic stage or P60 (ranging from P57 to
P78) until endpoint (i.e. NS 4 or the inability of mice to right themselves
within the first 10 s after being placed on either of their sides).
This endpoint occurred at approximately P160, concordant with the
average life expectancy of SOD1G93A mice in a C57BL/6J background
(157.1±9.3 days, The Jackson Laboratory) (Wooley et al., 2005).
Injections were administered to alternating sides of the abdomen to
minimize irritation, and administration was blinded for the investigator
carrying out injections and analysis.
Body weight measurements
Body weight was measured 4 times per week (evenly distributed during the
week), prior to each injection. Measurements were made at the same time
each day to minimize variation due to diurnal changes in food intake and
exercise. Body weight was used to assess disease onset, defined as the day
the animal was losing weight for 3 consecutive days without recovery
observed, corresponding to the body weight peak (Miana-Mena et al., 2005;
Leitner et al., 2009).
RotaRod performance
Motor coordination was measured with the RotaRod apparatus (Stoelting
Co.). The test, which measures the time mice are able to walk on a rotating
cylinder at increasing speed, was performed twice per week (evenly spread
during the week) and started with the start of treatment. Initial speed was
8 rpm, increased by 1 rpm every 8 s up to a maximum of 120 s. Before
treatment start, mice were trained for 3 consecutive days, with 5 repetitions
each day. Once trained, time spent walking on the RotaRod was annotated
and the value was the mean of three repetitions. As motor coordination is
highly variable between mice, the time spent on the RotaRod on the first day
of injection was considered as 100% for each individual; later values were
expressed as percentage of the initial value.
NeuroScore
As previously mentioned, the NeuroScore test (Hatzipetros et al., 2015) was
used to assess disease progression and neurological deficit in SOD1G93A
mice along the study. The test was performed 4 times per week (evenly
distributed during the week), prior to the injection of that day. Mice were
considered as pre-symptomatic, i.e. NS 0, when no tremor was observed in
the hindlimbs and they were able to walk normally. When tremor appeared
in the hindlimbs or these partially collapsed, animals were scored at NS
1. When toes curled downwards at least twice during a 75 cm walk, mice
were considered to be at NS 2. NS 3 implied rigid paralysis or minimal joint
movement in the hindlimbs, which were not used for forward motion.
Lastly, animals were considered to be at NS 4 when no forward motion was
observed and they were unable to right themselves within the first 10 s after
being placed on either of their sides. The NS 4 was considered to be the
humane endpoint of the study and considered for survival analysis. A
summary of the study design is shown in Fig. 2.
Fig. 7. Survival probability of SOD1G93A ALS mice administered i.p. 4 times per week with vehicle (in orange) or 30 mg/kg JNJ-47965567 (in green).
Survival endpoint was defined as the time mice were unable to right themselves after being placed on either body side. (A) Kaplan–Meier plot showing survival
probability in the whole group of mice. (B) Kaplan–Meier plot showing survival probability in the subset of male mice. (C) Kaplan–Meier plot showing survival
probability in the subset of female mice. Data analysis was performed using Cox regression, introducing age at first injection as a co-variable. Differences were
considered statistically significant at P<0.05.
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Tissue preparation and immunostaining
At the humane endpoint, a subset of mice was anesthetized (Dolethal,
50 mg/kg i.p.) and perfused through the ascending aorta with 0.9% NaCl
followed by 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB).
Wild-type age-matched mice were euthanized following the same protocol
to be used as controls. The caudal part of the spinal cord was excised by
dissecting it between vertebrae T9-T10 and the cauda equina. The
rostralmost 3 mm were cut off and, again, a transection was carried out
11 mm caudalwards. The piece obtained, which had in its center the lumbar
enlargement (segments L2-L6) (Harrison et al., 2013) was postfixed in 4%
buffered PFA for 24 h and cryoprotected for 2 days in 30% sucrose in 0.1 M
PB. The spinal blocks were frozen at oblique angles over the horizontal, and
serially cut at 40 µm in a sliding microtome (Leica SM2400, Leica
Biosystems, Nussloch, Germany). Every fourth section was processed for
free-floating immunostaining. After several washes in 0.1 M PB,
inactivation of endogenous peroxidase with 1% H2O2 in PB and
preincubation in a blocking solution with PBS, rabbit serum and 2%
Triton X-100 for 1 h, the sections were incubated with 1:100 anti-ChAT
(goat, RRID: AB_2079751, Cat# AB144P, Sigma-Aldrich), overnight at
4°C in agitation. This was followed by a 2-h incubation in biotinylated
secondary antibody 1:500 anti-goat (rabbit, RRID: AB_2336126, Cat# BA-
5000, Vector Laboratories). Sections were then incubated in avidin–biotin
solution (VECTASTAIN® Elite® ABC HRP Kit, #PK-6100, Vector
Laboratories) in 0.02 M PBS with 2% Triton X-100 and revealed in
0.05% 3,3′-diaminobenzidine (DAB) in 0.1 M PB, with 0.008% cobalt
chloride, 0.0064% nickel sulfate and 0.001% H2O2 added. Finally, sections
were mounted on glass slides, dehydrated, defatted and mounted on
coverslips using DePeX.
Microscopy and stereology
Spinal cord sections were examined and photographed using an Olympus
BX61 microscope. The total number of motor neurons was estimated
using the optical fractionator procedure (West et al., 1991) and
ChAT-immunoreactive cell bodies in the ventral horn as counting units.
This analysis was performed in an integrated stereological setup that
included an Olympus BX61 microscope with a high-precision motorized
microscope stage (Prior Proscan II, Prior Scientific Inc., Rockland, MA,
USA), a 0.3-µm resolution microcator and an Olympus DP71 camera. The
control of the stage movements and the interactive test grids were provided
by the NewCast stereological software (ver. 4.6.1.630, Visiopharm,
Hørsholm, Denmark). A plan apochromatic 100× oil immersion lens
(1.40 NA, UPlanSApo, Olympus) was used for neuron counting and for
estimating section thickness at each sampling point. On average, 73 neurons
were counted (ranging from 45 to 146). The precision of the estimates,
determined by estimating the coefficient of error (CE) as described for
systematic uniform random samples (Gundersen et al., 1999), was between
0.09 and 0.19 (mean=0.13). The investigator performing stereological
procedures was blinded to the treatment assigned to each case.
Western blots
At the humane endpoint, a subset of mice was anesthetized (Dolethal,
50 mg/kg i.p.) and perfused through the ascending aorta with 0.9% NaCl.
Non-treated SOD1G93A mice were euthanized at humane endpoint to be
used as controls. Spinal cord was dissected between vertebrae T9-T10 and
the cauda equina, and stored at−80°C. Proteins were extracted by sonication
in RIPA buffer with protease inhibitors and quantified using the Pierce™
BCA protein assay kit (#23227, ThermoFisher Scientific). 12%
polyacrylamide gels were casted for Iba-1 and hSOD1 analysis and 8%
gels for ChAT and P2X7R quantification. 30 μg of protein was loaded from
each sample, transferred to polyvinylidene fluoride (PVDF) membranes
(Immobilon-P, Merk Millipore), blocked for 1 h with 5% milk in TBST at
room temperature and incubated overnight with the following primary
antibodies diluted in 3.5% milk in TBST: 1:1000 anti-Iba-1 (rabbit, RRID:
AB_839504, Cat# 019-19741, FUJIFILM Wako Chemicals), anti-P2X7R
(1:200, rabbit, RRID: AB_2040068, Cat# APR-004, Alomone Labs), anti-
ChAT (1:500, goat, RRID: AB_2079751, Cat# AB144P, Sigma-Aldrich),
anti-hSOD1 (1:500, mouse, RRID:AB_10015296, Cat# MM-0070-2-P,
MediMabs), anti-β-actin (1:50000, mouse, peroxidase-conjugated, RRID:
AB_262011, Cat# A3854, Sigma-Aldrich). Membranes were washed with
TBST and incubated for 1 h at room temperature with the corresponding
secondary antibodies diluted in 3.5%milk in TBST (1:5000, goat anti-rabbit
IgG-HRP, RRID: AB_631746, Cat# sc-2004, Santa Cruz Biotechnology;
1:5000, donkey anti-goat IgG-HRP, RRID: AB_631728, Cat# sc-2020,
Santa Cruz Biotechnology, 1:5000 goat anti-mouse IgG-HRP, RRID:
AB_631737, Cat# sc-2031, Santa Cruz Biotechnology). Membranes were
washed with TBST, incubated with Clarity Western ECL substrate
(#1705061, BioRad) and chemiluminescence was detected with the
ChemiDoc™ XRS+ System (#1708265, BioRad).
Fig. 8. ChAT immunolabeling ofWTandSOD1G93Amice at endpoint stage. (A,B,D-G) Staining of spinal cords for ChAT reveals a reduction in the total number
of motor neurons, together with degenerative changes in cell bodies and neurites in vehicle-treated SOD1G93A ALS mice (D-G) compared with age-matched
wild-type animals (A,B). (C) Decrease in number approached a highly significant 50% in both vehicle- and JNJ-47965567-treated animals of mixed sexes (n=6).
Data are shown as mean±s.e.m. (E) Motor axons exiting the ventral horn in the ventral root show abundant swellings and probable vacuolations (arrows in E).
(F) Similar dilatations are often found in thickened dendrites. Moreover, ChAT-positive profiles, probably representing remnants of neuronal perikarya (G),
intermingle with a modest number of large neurons that show strong ChAT labeling (D). Scale bars: 50 µm (A,D); 10 µm (B,E-G).
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Data and statistical analysis
For survival and disease onset analysis, Cox regression test was performed,
introducing a correction for the variation on age at first injection. Disease
onset was considered as the day animals were losing weight for the third day
in a row without recovery.
For weight variation, RotaRod and NeuroScore data, D’Agostino–
Pearson test was applied to analyze data normality. If data followed a normal
distribution, an unpaired Student’s t-test comparing the mean of data points
of vehicle and treatment was used. If data did not follow a normal
distribution, the non-parametric Mann–Whitney test was used to compare
the two groups.
For motor neuron number and western blot analysis, D’Agostino–Pearson
test was applied to analyze the normality of the data, and normal data were
analyzed with ordinary one-way ANOVA and post hoc Tukey’s multiple
comparisons test.
Data were analyzed with GraphPad Prism 7 and IBM SPSS Statistics.
Statistical differences with P<0.05 were considered significant. The data and
statistical analyses comply with the recommendations on experimental
design and analysis in pharmacology (Curtis et al., 2018).
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Miana-Mena, F. J., Mun ̃oz, M. J., Yagüe, G., Mendez, M., Moreno, M., Ciriza, J.,
Zaragoza, P. and Osta, R. (2005). Optimal methods to characterize the G93A
mouse model of ALS. Amyotroph. Lateral Scler. 6, 55-62. doi:10.1080/
14660820510026162
Parisi, C., Napoli, G., Pelegrin, P. and Volonté, C. (2016). M1 and M2 functional
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